Recombinant human erythropoietin therapy is very effective after an autologous peripheral blood stem cell transplant when started soon after engraftment.
暂无分享,去创建一个
[1] F. Baron,et al. Once weekly recombinant human erythropoietin therapy is very efficient after allogeneic peripheral blood stem cell transplantation when started soon after engraftment. , 2003, Haematologica.
[2] F. Baron,et al. Erythropoiesis after nonmyeloablative stem-cell transplantation is not impaired by inadequate erythropoietin production as observed after conventional allogeneic transplantation , 2002, Transplantation.
[3] F. Baron,et al. Optimization of recombinant human erythropoietin therapy after allogeneic hematopoietic stem cell transplantation. , 2002, Experimental hematology.
[4] Y. Beguin. Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients. , 2002, Haematologica.
[5] G. Fillet,et al. Influence of marrow erythropoietic activity on serum erythropoietin levels after autologous hematopoietic stem cell transplantation. , 1998, Haematologica.
[6] G. Leone,et al. High-dose carboplatin, etoposide and melphalan (CEM) with peripheral blood progenitor cell support as late intensification for high-risk cancer: non-haematological, haematological toxicities and role of growth factor administration. , 1997, British Journal of Cancer.
[7] I. Macdougall,et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. , 1996, Kidney international.
[8] A. Bosi,et al. Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial. , 1996, Bone marrow transplantation.
[9] G. Scambia,et al. The combination of erythropoietin and granulocyte colony‐stimulating factor increases the rate of haemopoietic recovery with clinical benefit after peripheral blood progenitor cell transplantation , 1996, British journal of haematology.
[10] L. Ponchio,et al. Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy. , 1996, Haematologica.
[11] B. Sautois,et al. Quantitative assessment of erythropoiesis in haemodialysis patients demonstrates gradual expansion of erythroblasts during constant reatment with recombinant human erythropoietin , 1995, British journal of haematology.
[12] F. Mandelli,et al. A controlled trial of recombinant human erythropoietin after bone marrow transplantation. , 1994, Blood.
[13] C. Miller,et al. Erythropoietin after bone marrow transplantation. , 1994, Hematology/oncology clinics of North America.
[14] B. W. Brown,et al. A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. , 1994, Blood.
[15] G. Demetri,et al. Recombinant human erythropoietin for the treatment of the anaemia associated with autologous bone marrow transplantation , 1994, British journal of haematology.
[16] F. Locatelli,et al. Use of recombinant human erythropoietin after bone marrow transplantation in pediatric patients with acute leukemia: effect on erythroid repopulation in autologous versus allogeneic transplants. , 1994, Bone marrow transplantation.
[17] G. Fillet,et al. Dynamics of erythropoietic recovery following bone marrow transplantation: role of marrow proliferative capacity and erythropoietin production in autologous versus allogeneic transplants. , 1993, Bone marrow transplantation.
[18] J. Nemunaitis,et al. Use of granulocyte-macrophage colony-stimulating factor and erythropoietin in combination after autologous marrow transplantation. , 1993, Bone Marrow Transplantation.
[19] G. Fillet,et al. Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. , 1993, Blood.
[20] A. Pedrazzini. Erythropoietin and GM-CSF following autologous bone marrow transplantation. , 1993, European journal of cancer.
[21] B. Sautois,et al. Early prediction of response to recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibrinogen. , 1993, Blood.
[22] G. Poggi,et al. Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia. , 1992, Haematologica.
[23] G. Fillet,et al. Circulating erythropoietin levels after bone marrow transplantation: inappropriate response to anemia in allogeneic transplants , 1991 .
[24] G. Fillet,et al. Serum immunoreactive erythropoietin during pregnancy and in the early postpartum , 1990, British journal of haematology.
[25] M. Koury,et al. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. , 1990, Science.
[26] C. Finch,et al. Transferrin receptors in rat plasma. , 1988, Proceedings of the National Academy of Sciences of the United States of America.